SEER Inquiry System - Search

Solid Tumor Rules/Multiple Primaries--Lung:  How many cases should be abstracted for a patient with 2022 wedge biopsy of right upper lobe acinar predominant lung adenocarcinoma and wedge biopsy of right lower lobe lepidic predominant adenocarcinoma if there is concern for diffuse spread throughout the lungs secondary to the lymphangitic carcinomatosis and possible diffuse pneumonic type of adenocarcinoma? See Discussion.

First Course Treatment/Immunotherapy--Other Therapy:  Should all therapies given as part of a clinical trial be coded as Other Therapy (NAACCR #1420), or only those that cannot be classified in one of the other treatment categories (systemic therapy, surgery, radiation) or as ancillary treatments?  Does it matter what is listed in SEER*Rx under Primary Sites or Remarks regarding FDA approvals?  See Discussion.

Solid Tumor Rules/Multiple Primaries--Head and Neck:  Is a patient with 2020 neck mass, squamous cell carcinoma (SCC), p16-negative, who then had a biopsy of the right tonsil (C09.9) in July 2022, SCC p16-positive, one or two primaries? Is this coded to 8070/3 using pre-2022 rules or a new, second primary p16-positive, 8085/3.  See Discussion.

First Course Treatment/Immunotherapy--Other Therapy:  Should IMC-A12 (Cixutumumab) be coded as Immunotherapy/Biological Response Modifier (BRM) treatment?  See Discussion.

Solid Tumor Rules (2018/2021)/Histology--Head & Neck:  What is the histology code for a uvula (C052) primary with histology of squamous cell carcinoma, conventional (keratinizing) and p16 result is negative? See Discussion.

First Course Treatment/Neoadjuvant Therapy--Melanoma:  How are the three Neoadjuvant Therapy data items (Neoadjuvant Therapy, Neoadjuvant Therapy--Clinical Response, Neoadjuvant Therapy--Treatment  Effect) coded when a patient is diagnosed with melanoma in the lymph nodes with no primary skin site identified? The physician gives immunotherapy as neoadjuvant therapy with planned and carried out surgical resection of involved lymph nodes following completion of immunotherapy. There is no "planned definitive surgical resection of the primary site" as no primary site was found,

First Course Treatment/Radiation Therapy:  How should Lutathera be coded? CoC states XRT- Radioisotopes and SEER states Other Treatment.

Primary Site/Histology--Intrahepatic Duct:  How are primary site and histology coded for cholangiocarcinoma cases when the pathology only shows a liver tumor and other involvement.  See Discussion.

Laterality--Brain and CNS: Can Laterality be coded as 5 (midline) for a sella turcica meningioma (or tuberculum sellae meningioma) when no other statement regarding tumor laterality is documented? See Discussion.

Reportability/Histology--Eye:  Is “squamous mucosa with high grade dysplasia” equivalent to a diagnosis of “high grade squamous dysplasia?” See Discussion.